ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update of ...

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® ...

Revenue (Q4 2023): $13.4 million, down $2.3 million from Q4 2022. Gross Margin (Q4 2023): 34%, consistent with Q4 2022. Operating Loss (Q4 2023): $3.8 million, improved from $8.2 million in Q4 2022.

Good morning. And welcome to PDS Biotech's call to discuss the company's Year-End 2023 Financial Results and Clinical Strategy Update Conference Call. All participants are currently in listen-only ...

Good afternoon. My name is Alicia, and I'll be your conference call operator today. At this time, all participants are in a listen-only mode. After the speakers' formal remarks, there will be a ...

R&D Innovation to Lead the Future, Deepening Customer Value Creation From the performance during the 2023 reporting period, GenScript Group's overall development is optimistic, with each business ...